Beck Mack & Oliver LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 362,788 shares of the biopharmaceutical company’s stock after selling 18,765 shares during the quarter. Beck Mack & Oliver LLC’s holdings in Gilead Sciences were worth $25,990,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kovack Advisors Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth $2,023,000. First Western Capital Management Co boosted its stake in shares of Gilead Sciences by 2.6% during the 4th quarter. First Western Capital Management Co now owns 37,548 shares of the biopharmaceutical company’s stock worth $2,690,000 after acquiring an additional 949 shares in the last quarter. Arlington Financial Advisors LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $2,132,000. Harrington Investments INC boosted its stake in shares of Gilead Sciences by 6.7% during the 4th quarter. Harrington Investments INC now owns 24,320 shares of the biopharmaceutical company’s stock worth $1,742,000 after acquiring an additional 1,536 shares in the last quarter. Finally, CIBC World Markets Inc. boosted its stake in shares of Gilead Sciences by 1.1% during the 4th quarter. CIBC World Markets Inc. now owns 654,161 shares of the biopharmaceutical company’s stock worth $46,864,000 after acquiring an additional 7,378 shares in the last quarter. 77.96% of the stock is owned by institutional investors and hedge funds.
In related news, Director Gayle E. Wilson sold 60,000 shares of Gilead Sciences stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the sale, the director now directly owns 182,258 shares of the company’s stock, valued at $14,201,543.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total value of $1,108,050.00. Following the sale, the executive vice president now directly owns 64,613 shares in the company, valued at $4,772,962.31. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 424,435 shares of company stock worth $33,602,330. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period last year, the company earned $2.70 earnings per share. Gilead Sciences’s quarterly revenue was down 18.7% compared to the same quarter last year. analysts predict that Gilead Sciences, Inc. will post 6.21 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a $0.57 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.81%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 27.05%.
Several equities research analysts have recently weighed in on GILD shares. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. Royal Bank of Canada reissued a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a research note on Friday, February 23rd. BMO Capital Markets raised their price objective on Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research note on Thursday, February 8th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective for the company. in a research note on Wednesday, January 17th. Finally, Credit Suisse Group lowered Gilead Sciences from an “outperform” rating to a “neutral” rating and increased their target price for the company from $74.35 to $80.00 in a report on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $87.75.
ILLEGAL ACTIVITY WARNING: “Beck Mack & Oliver LLC Decreases Holdings in Gilead Sciences, Inc. (GILD)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/13/beck-mack-oliver-llc-decreases-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.